A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

NCT05367401 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped waiting for update from Study Lead

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions

DRUG: Sabatolimab
DRUG: Magrolimab
DRUG: Azacitidine

Sponsor

Novartis Pharmaceuticals